



# An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab

21/02/2025 12:04:26

## Main Information

**Primary registry identifying number**

LBCTR2021034775

**Protocol number**

COMB157G23101

**MOH registration number**

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify**

**Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

**Primary sponsor**

Novartis Pharma Services Inc.

**Primary sponsor: Country of origin**

Novartis Pharmaceuticals

**Date of registration in primary registry**

11/11/2021

**Date of registration in national regulatory agency**

**Public title**

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab

**Acronym**

**Scientific title**

A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy

**Acronym**

**Brief summary of the study: English**

The open label study to evaluate effectiveness of treatment with ofatumumab in patients transitioning from commonly used oral MS therapies - fingolimod or dimethyl fumarate, due to breakthrough disease.

**Brief summary of the study: Arabic**

دراسة تقدّمية متعددة المراكز مفتوحة اللصافة ذات مجموعة واحدة لتقييم فعالية العلاج بأوفاتوموماب والنتائج التي يفيد عنها المرضى المصابين بالتصلب اللويحي الانتكاسي الذين ينتقلون من العلاج بثنائي ميثيل الفومارات أو بفينغوليمود

**Health conditions/problem studied: Specify**

Relapsing Multiple Sclerosis

**Interventions: Specify**

Biological: Ofatumumab

Patients in the ofatumumab will receive injections of ofatumumab provided in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)

Other Name: OMB157





## Key inclusion and exclusion criteria: Inclusion criteria

### Inclusion Criteria:

Diagnosis of multiple sclerosis (MS)  
Relapsing MS (RRMS or SPMS) course  
Subject transitioning from either fingolimod or dimethyl fumarate, following min 6 months treatment with either drug  
Breakthrough disease as evidence by clinical relapses or MRI  
EDSS score of 0 to 4

## Key inclusion and exclusion criteria: Gender

Both

## Key inclusion and exclusion criteria: Specify gender

## Key inclusion and exclusion criteria: Age minimum

18

## Key inclusion and exclusion criteria: Age maximum

60

## Key inclusion and exclusion criteria: Exclusion criteria

Primary progressive MS or SPMS without disease activity  
Disease duration of more than 10 years since diagnosis  
Patients with an active chronic disease of the immune system other than MS  
Patients at risk of developing or having reactivation of hepatitis  
Patients with active systemic infections or with neurological findings consistent with PML Other protocol-defined inclusion/exclusion criteria may apply

## Type of study

Interventional

## Type of intervention

Pharmaceutical

## Type of intervention: Specify type

N/A

## Trial scope

Therapy

## Trial scope: Specify scope

N/A

## Study design: Allocation

Single Arm Study

## Study design: Masking

Open (masking not used)

## Study design: Control

N/A

## Study phase

3

## Study design: Purpose

Treatment

## Study design: Specify purpose

N/A

## Study design: Assignment

Single

## Study design: Specify assignment

N/A

## IMP has market authorization

Yes, Worldwide

## IMP has market authorization: Specify

US, UAE, Albania, Argentina, Canada, Singapore, Switzerland

## Name of IMP

Ofatumumab

## Year of authorization

## Month of authorization

## Type of IMP

Immunological

## Pharmaceutical class

Monoclonal antibodies

## Therapeutic indication

Patients with:  
relapsing multiple sclerosis

**Therapeutic benefit**

potential efficacy of ofatumumab in patients with relapsing MS.

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration****Target follow-up duration: Unit****Number of groups/cohorts****Biospecimen retention**

Samples without DNA

**Biospecimen description**

Covance Central lab : Ambient and Frozen conditions

**Target sample size**

10

**Actual enrollment target size****Date of first enrollment: Type**

Anticipated

**Date of first enrollment: Date**

29/04/2021

**Date of study closure: Type**

Anticipated

**Date of study closure: Date**

25/06/2025

**Recruitment status**

Pending

**Recruitment status: Specify****Date of completion**

31/08/2022

**IPD sharing statement plan**

Yes

**IPD sharing statement description**

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)

**Additional data URL**

[https://clinicaltrials.gov/ct2/show/record/NCT04353492?  
term=ofatumumab+treatment+effectiveness&cond=relapsing+multiple+sclerosis+transitioning&draw=2&rank=1](https://clinicaltrials.gov/ct2/show/record/NCT04353492?term=ofatumumab+treatment+effectiveness&cond=relapsing+multiple+sclerosis+transitioning&draw=2&rank=1)

**Admin comments****Trial status**

Approved

## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
NCT04353492	Clinical trials.gov

## Sources of Monetary or Material Support

Name
Novartis Pharma services Inc.

## Secondary Sponsors

Name
NA

## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Taghrid El Hajj	Beirut	Lebanon	9613494008	taghridelhajj@gmail.com	Rafik Hariri University Hospital
Scientific	Hind Khairallah	Sinelfil	Lebanon	01512002#271	Hind.khairallah@fattal.com.lb	Khalil Fattal et Fils s.a.l
Public	Halim Abboud	Beirut	Lebanon	9613535711	halimabboud@hotmail.com	Hotel Dieu De France
Public	Salam Koussa	Beirut	Lebanon	9613726771	drkoussa@hotmail.com	Lebanese Geitaoui Hospital
Public	Samia Khoury	Beirut	Lebanon	9611350000#7422	sk88@aub.edu.lb	American University of Beirut Medical Center



## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Rafik Hariri University Hospital	Taghrid El Hajj	Neurology	Approved
Hotel Dieu De France	Halim Abboud	Neurology	Approved
Lebanese Hospital Geitaoui	Salam Koussa	Neurology	Approved
American University of Beirut Medical Center	Samia Khoury	Neurology	Approved

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Rafic Hariri University Hospital	02/12/2020	Rawan Yammout	rawan.yammout@crurhuh.com	018300000 ext 2037
Hotel Dieu de France	03/11/2020	Sami Richa	cue@usj.edu.lb	961421229
Hopital Libanais Getaoui Centre Hospitalier Universitaire	23/03/2021	Raja Chaftari	irb@hopital-libanais.com	961 1 590 000 # 8872 8859
American University of Beirut Medical Center	25/05/2021	Fuad Ziyadeh	fz05@aub.edu.lb	9611350000#5445



Countries of Recruitment	
Name	
Lebanon	
Australia	
Austria	
Belgium	
Bulgaria	
Czech Republic	
Germany	
Greece	
Hungary	
Norway	
Poland	
Portugal	
Russian Federation	
Slovakia	
Spain	
Switzerland	
Turkey	
United States of America	

Health Conditions or Problems Studied		
Condition	Code	Keyword
Relapsing Multiple sclerosis	Multiple sclerosis (G35)	MS



## Interventions

Intervention	Description	Keyword
Informed Consent form , IMP administration , Visit assessment and schedule	Informed Consent form , IMP administration , Visit assessment and schedule	ICF, IMP

## Primary Outcomes

Name	Time Points	Measure
Annual Relapse Rate	96 weeks	number of confirmed relapses in a year calculated based on cumulative number of relapses by patient adjusted for time-in-study by patient

## Key Secondary Outcomes

Name	Time Points	Measure
Safety evaluation	96 weeks	Proportion of patients with adverse events, including injection related reactions, abnormal laboratory results or vital signs as well as proportion of patients discontinuing treatment due to insufficient effectiveness or safety



## Trial Results

**Summary results**

**Study results globally**

**Date of posting of results summaries**

**Date of first journal publication of results**

**Results URL link**

**Baseline characteristics**

**Participant flow**

**Adverse events**

**Outcome measures**

**URL to protocol files**